Partners Lawrence Vernaglia and Nathaniel Lacktman were quoted in a Fox News piece, “Virtual Doctors Treat Real Patients at Remote Digital Clinics,” on March 6, 2015. The article discusses advances in technology and the growing use of telemedicine at remote medical clinics.
Vernaglia was quoted saying, “There are many viable options for getting compensated for practicing telemedicine. The smartest thing organizations can do now is to continue developing programs, and be ready for the law to catch up – because it will.”
Lacktman was quoted saying, “Telemedicine offers new ways for providers to manage this level of risk and keep their patients healthy, happy and out of the hospital.”
Vernaglia was quoted saying, “There are many viable options for getting compensated for practicing telemedicine. The smartest thing organizations can do now is to continue developing programs, and be ready for the law to catch up – because it will.”
Lacktman was quoted saying, “Telemedicine offers new ways for providers to manage this level of risk and keep their patients healthy, happy and out of the hospital.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”